Tigestol is an Estrene derivative patented by Organon Laboratories Ltd. as an anabolic, androgenic, and progestative agent.

Examorelin (Hexarelin) is a hexapeptide (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) that stimulates the release of growth hormone lease through binding to the growth hormone secretagogue receptor (GHSR). Hexarelin might have direct cardiovascular actions beyond growth hormone release and neuroendocrine effects. Europeptides and Mediolanum Farmaceutici were developing examorelin for the treatment of somatotropin deficiency.

Almestrone (7 alpha-methylestrone) is a synthetic steroidal estrogen. It is a precursor of several highly active steroidal hormones.

Verucerfont (formerly GSK561679), a corticotropin releasing factor (CRF) receptor 1 antagonist, is being developed by GlaxoSmithKline under the license from Neurocrine Biosciences, for the treatment of post-traumatic stress disorder and congenital adrenal hyperplasia (CAH). Verucerfont is a potent, selective CRF1 receptor antagonist (IC50 for CRF1, CRF2, and CRF-BP ~ 6.1, >1000 and >1000 nM, respectively), and is orally available and brain penetrant. Verucerfont is in phase II clinical trials for the treatment of post-traumatic stress disorder or alcoholism. The compound was also in trials for the treatment of classic congenital adrenal hyperplasia (CAH). However, this research has been discontinued. In 2015, orphan drug designation was received in U.S. for the indication.

Clogestone Acetate (AY-11440) is a steroidal progestin that was synthesized in 1964 and was investigated as a progestin-only contraceptive but was never marketed.

Trestolone is a synthetic androgen that inhibits the release of follicle-stimulating hormone and impairs spermatogenesis. Luteinizing hormone is also suppressed, which cuts production of testosterone. The azoospermia and oligospermia are reversible after discontinuation of trestolone. Trestolone has androgenic and anabolic properties and loss of secondary sex characteristics is not seen. Like testosterone, trestolone undergoes enzymatic aromatization to an estrogen. The use of trestolone instead of testosterone for androgen replacement therapy could have health-promoting effects by reducing the occurrence of prostate disease. Trestolone had been in phase II clinical trial for the andropause control. However, this development was discontinued.

Propetandrol is a pregnanediol derivative patented by Schering A.-G. as long-acting anabolic androgen. Propetandrol is potent in the prevention of tissue calcification and skeletal lesions.

Orotirelin (previously known as CG 3509) was investigated as a thyrotropin-releasing hormone. Experiments on rats have shown that compound could increase dopamine release from rodent brain. Information about the current study of this drug is not available.

Clostebol is a synthetic anabolic-androgenic steroid, a derivative of the natural hormone testosterone. Clostebol is a Schedule III controlled substance used medically in topical ophthalmologic and dermatologic treatments. Due to potential use as a performance-enhancing drug, clostebol is banned by the World Anti-Doping Agency.

ITROCINONIDE is a synthetic corticosteroid which showed no signs of systemic activity (cortisol depression).